Approved comparison material connected to this topic.
7 total recordsSource comparisons are presented without a generated winner.
Typical Dose 200–500 mcg nightly 200 mcg sermorelin + 100 mcg GHRP-2 200 mcg sermorelin + 200 mcg ipamorelin Combination protocols produce 40–60% higher peak GH vs monotherapy IGF-1 Increase (12 weeks) 30–50% …
Standard nightly 200–300 mcg 15–30 min pre-sleep 5 days on / 2 off weekly 250–300 ng/mL Baseline protocol for most researchers. Reliable GH pulse amplification without receptor saturation High-dose pulsatile 4…
Mechanism Stimulates pituitary GHRH receptors to release endogenous GH in pulses Directly replaces GH; bypasses pituitary Sermorelin preserves regulatory feedback; GH does not GH Release Pattern Pulsatile (mim…
Clinical aging-intervention studies use subcutaneous administration exclusively. Intramuscular injection offers no bioavailability advantage and increases injection-site discomfort. The table below compares st…
Sermorelin GHRH analog. Stimulates endogenous GH pulse from pituitary 8–12 weeks for body composition; 6+ months for skin/collagen Daily subcutaneous injection (bedtime) Prescription required; not FDA-approved…
Sermorelin (200–500 mcg nightly) GHRH analog. Stimulates endogenous pulsatile GH release from the pituitary 30–50% above baseline within 8–12 weeks $150–$250 (including medication and supplies) Legal. Not a co…
Sermorelin GHRH analogue. Stimulates pituitary GH release 8–12 minutes Once daily (before sleep) 20–35% increase from baseline Preserves endogenous GH pulsatility; lowest risk of receptor desensitisation CJC-1…